about pulmatrix

Pulmatrix is a clinical stage biotechnology company developing a new class of inhaled therapies that harness the body’s natural host defenses and immune response in the airway to safely prevent and treat respiratory infections, reduce inflammation, and prevent acute exacerbations in patients with chronic inflammatory airway disease.

iCALM is comprised of combinations of simple cationic salts administered by oral aerosol inhalation from a convenient, handheld inhaler. Our novel therapies — inhaled cationic airway lining modulators (iCALM) — trigger multiple distinct mechanisms that act in concert with inherent biophysical properties and host defenses of the airway. As a host-targeted therapy, iCALM offers broad spectrum protection against infectious respiratory pathogens and reduces inflammatory responses in the airway. iCALM therapies may have broad application for respiratory diseases such as COPD, asthma, and cystic fibrosis and respiratory infections including influenza, influenza-like illness (ILI), rhinovirus, ventilator associated pneumonia (VAP) and respiratory syncytial virus (RSV).

Pulmatrix is developing a broad pipeline to prevent and treat a range of respiratory diseases which have considerable unmet medical need. The Company has built an impressive package of pre-clinical data demonstrating treatment efficacy, prophylaxis, and transmission control in multiple animal species, in both viral and bacterial diseases, as well as reduced inflammation in acute models of lung injury and allergic asthma. Pulmatrix has successfully completed pre-clinical safety studies in two species with liquid and dry powder iCALM (DP) as well as Phase 1 testing of liquid iCALM in healthy normal volunteers (HNV).